CONQUEST: The COllaboratioN on QUality improvement initiative for achieving Excellence in Standards of COPD care
Introducing CONQUEST
The COllaboratioN on QUality improvement initiative for achieving Excellence in Standards of COPD care (CONQUEST) is a novel, collaborative, interventional COPD registry. It comprises an integrated quality improvement program focusing on patients (diagnosed and undiagnosed) at a modifiable and higher risk of COPD exacerbations. CONQUEST is underpinned by 4-evidence based Quality Standards developed by 11 experts internationally recognized in their field.
CONQUEST drives long-term, targeted, patient-centred changes in COPD management. The promotion of expert and guideline-led care aims to reduce exacerbation frequency and improve health care outcomes
Quality Improvement Program
About the CONQUEST quality improvement programme
A program supporting healthcare teams to identify opportunities for improved diagnosis, care and management of their COPD patients. The four quality standards have been translated into a program of activities that embed quality improvement into routine care.
If you are interested in implementing CONQUEST in your healthcare system, or wish to find out more about the program and the resources available please contact the team at:
info.conquest@optimumpatientcare.org
Publications and Media
CONQUEST US Opportunity Analysis
Margee Ker, Yasir Tarabichi, Alexander Evans, Douglas Mapel, Wilson Pace, Victoria Carter, Amy Couper, M Bradley Drummond, Norbert Feigler, Alex Federman, Hitesh Gandhi, Nicola A Hanania, Alan Kaplan, Konstantinos Kostikas, Maja Kruszyk, Marije van Melle, Hana Müllerová, Ruth Murray, Jill Ohar, Michael Pollack, Rachel Pullen, Dennis Williams, Juan Wisnivesky, MeiLan K Han, Catherine Meldrum, David Price. Patterns of care in the management of high-risk COPD in the US (2011-2019): an observational study for the CONQUEST quality improvement program. Lancet Reg Health Am. 2023
CONQUEST UK Opportunity Analysis
David M. G. Halpin, Andrew P. Dickens, Derek Skinner, Ruth Murray, Mukesh Singh, Katherine Hickman, Victoria Carter, Amy Couper, Alexander Evans, Rachel Pullen, Shruti Menon, Tamsin Morris, Hana Muellerova, Mona Bafadhel, James Chalmers, Graham Devereux, Martin Gibson, John R. Hurst, Rupert Jones, Konstantinos Kostikas, Jennifer Quint, Dave Singh, Marije van Melle, Tom Wilkinson, David Price. Identification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study. Lancet Reg Health Eur. 2023
CONQUEST QUALITY STANDARDS
Rachel Pullen, Marc Miravitlles, Anita Sharma, Dave Singh, Fernando Martinez, John R Hurst, Luis Alves, Mark Dransfield, Rongchang Chen, Shigeo Muro, Tonya Winders, Christopher Blango, Hana Muellerova, Frank Trudo, Paul Dorinsky, Marianna Alacqua, Tamsin Morris, Victoria Carter, Amy Couper, Rupert Jones, Konstantinos Kostikas, Ruth Murray, David B Price. CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. Int J Chron Obstruct Pulmon Dis 2021.
CONQUEST: A QUALITY IMPROVEMENT PROGRAM FOR DEFINING AND OPTIMIZING STANDADRDS OF CARE FOR MODIFIABLE HIGH-RISK COPD PATIENTS
Luis Alves, Rachel Pullen, John R Hurst, Marc Miravitlles, Victoria Carter, Rongchang Chen, Amy Couper, Mark Dransfield, Alexander Evans, Antony Hardjojo, David Jones, Rupert Jones, Margee Kerr, Konstantinos Kostikas, Jonathan Marshall, Fernando Martinez, Marije van Melle, Ruth Murray, Shigeo Muro, Clementine Nordon, Michael Pollack, Chris Price, Anita Sharma, Dave Singh, Tonya Winders, David B Price. CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients. Patient Relat Outcome Meas 2022.
NETWORK
CONQUEST Network and Database
.png)
A European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP®) Registered Datasource (ENCEPP/DSPP/42512)
CONTACT
For further information on the CONQUEST quality improvement program please contact the team at:
5 Coles Lane Oakington Cambridgeshire CB24 3BA UK
CONQUEST is co-funded by Optimum Patient Care Global Limited and AstraZeneca Ltd. AstraZeneca is the sole external funder of this work.
Optimum Patient Care’s Facilities and Administration Costs Policies (for US institutions / projects only) It is the policy of Optimum Patient Care Limited (OPC) to charge facilities and administration fees (F&A) for grants and contracts undertaken by OPC. In cases other than where a set federal F&A rate has been established, OPC will accept the specific F&A rate publicly established by a given not-for-profit funding agency for grant or contract activities as long as it meets or exceeds the currently established OPC minimum rate. The minimum acceptable F&A rate of OPC is 10% without special dispensation. The F&A rate for industry funded grants and contracts is 25% and it is OPC policy to not pay a higher rate than this. OPC will distribute F&A fees to sub-contractors prorated to the direct costs included in the sub-contract. OPC will pay sub-contractors the facilities and administration percentage of direct costs as established by the specific funding agency for a particular grant, or for federal grants at the established federal rate for the sub-contractor. OPC will also collect facility and administration fees on the first $25,000 of a sub-contract for the life of a grant or contract. The sub-contractor may also request facilities and administration fees for the initial $25,000 of a sub-contract. If duplicate facilities and administration fees are not allowed for sub-contracts by a funding agency then the fees associated with the first $25,000 of direct costs will be equally paid to the sub-contractor and OPC. OPC does not pay facilities and administration fees for purchased services or consultation services.